Moreover, CASC2 was found downregulated in malignant melanoma, and low CASC2 expression was correlated with tumor size, TNM stage, and poor overall and disease-free survival (DFS) of malignant melanoma patients [13]. The gene discussed is CASC2; the disease is melanoma.